Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
The PP-based top and bottom webs are manufactured in a unique coextrusion process
Medical Device Policy is a progressive step in propelling the country towards Atmanirbharta in the heavily import dependent Medical Device Sector
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Subscribe To Our Newsletter & Stay Updated